Evidence from C57BL/6 mice suggests that CD8 + T cells, specific to the immunodominant HSV-1 glycoprotein B (gB) H-2 b -restricted epitope (gB [498][499][500][501][502][503][504][505] ), protect against ocular herpes infection and disease. However, the possible role of CD8 + T cells, specific to HLA-restricted gB epitopes, in protective immunity seen in HSV-1-seropositive asymptomatic (ASYMP) healthy individuals (who have never had clinical herpes) remains to be determined. In this study, we used multiple prediction algorithms to identify 10 potential HLA-A*02:01-restricted CD8 + T cell epitopes from the HSV-1 gB amino acid sequence. Six of these epitopes exhibited high-affinity binding to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01-positive, HSV-1-seropositive ASYMP individuals, the most frequent, robust, and polyfunctional CD8 + T cell responses, as assessed by a combination of tetramer, IFN-γ-ELISPOT, CFSE proliferation, CD107a/b cytotoxic degranulation, and multiplex cytokine assays, were directed mainly against epitopes gB [342][343][344][345][346][347][348][349][350] and gB [561][562][563][564][565][566][567][568][569] . In contrast, in 10 HLA-A*02:01-positive, HSV-1-seropositive symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent clinical herpes disease) frequent, but less robust, CD8 + T cell responses were directed mainly against nonoverlapping epitopes (gB [183][184][185][186][187][188][189][190][191] and gB [441][442][443][444][445][446][447][448][449] ). ASYMP individuals had a significantly higher proportion of HSV-gBspecific CD8 + T cells expressing CD107a/b degranulation marker and producing effector cytokines IL-2, IFN-γ, and TNF-α than did SYMP individuals. Moreover, immunization of a novel herpes-susceptible HLA-A*02:01 transgenic mouse model with ASYMP epitopes, but not with SYMP epitopes, induced strong CD8 + T cell-dependent protective immunity against ocular herpes infection and disease. These findings should guide the development of a safe and effective T cell-based herpes vaccine.
Evidence from C57BL/6 mice suggests that CD8 + T cells, specific to the immunodominant HSV-1 glycoprotein B (gB) H-2 b -restricted epitope (gB [498] [499] [500] [501] [502] [503] [504] [505] ), protect against ocular herpes infection and disease. However, the possible role of CD8 + T cells, specific to HLA-restricted gB epitopes, in protective immunity seen in HSV-1-seropositive asymptomatic (ASYMP) healthy individuals (who have never had clinical herpes) remains to be determined. In this study, we used multiple prediction algorithms to identify 10 potential HLA-A*02:01-restricted CD8 + T cell epitopes from the HSV-1 gB amino acid sequence. Six of these epitopes exhibited high-affinity binding to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01-positive, HSV-1-seropositive ASYMP individuals, the most frequent, robust, and polyfunctional CD8 + T cell responses, as assessed by a combination of tetramer, IFN-γ-ELISPOT, CFSE proliferation, CD107a/b cytotoxic degranulation, and multiplex cytokine assays, were directed mainly against epitopes gB [342] [343] [344] [345] [346] [347] [348] [349] [350] and gB [561] [562] [563] [564] [565] [566] [567] [568] [569] . In contrast, in 10 HLA-A*02:01-positive, HSV-1-seropositive symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent clinical herpes disease) frequent, but less robust, CD8 + T cell responses were directed mainly against nonoverlapping epitopes (gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB [441] [442] [443] [444] [445] [446] [447] [448] [449] ). ASYMP individuals had a significantly higher proportion of HSV-gBspecific CD8 + T cells expressing CD107a/b degranulation marker and producing effector cytokines IL-2, IFN-γ, and TNF-α than did SYMP individuals. Moreover, immunization of a novel herpes-susceptible HLA-A*02:01 transgenic mouse model with ASYMP epitopes, but not with SYMP epitopes, induced strong CD8 + T cell-dependent protective immunity against ocular herpes infection and disease. These findings should guide the development of a safe and effective T cell-based herpes vaccine.
A staggering number of individuals carry HSV-1 and/or HSV-2 that cause a wide range of diseases throughout their life (1) (2) (3) (4) (5) . Most HSV-infected individuals are asymptomatic (ASYMP). They do not experience any recurrent herpetic disease (e.g., cold sore, ocular and genital herpes) even though spontaneously reactivated virus is surreptitiously shed in their body fluids (e.g., saliva, tears, and vaginal secretions) multiple times each year (1-3, 6, 7) . In contrast, a small proportion of HSV-seropositive individuals are symptomatic (SYMP) and experience endless recurrences of herpetic disease, usually multiple times a year (8, 9) , often requiring continuous antiviral therapy (i.e., acyclovir and derivatives). Additionally, in some HSV-1-seropositive SYMP individuals, sporadic reactivation of the virus from latency and corneal reinfection can cause blinding recurrent herpetic stromal keratitis (rHSK), a T cell-mediated immunopathological lesion of the cornea (10) (11) (12) . Understanding the immune mechanisms by which ASYMP individuals, who spontaneously shed virus at the same frequency as SYMP individuals, control herpetic disease should prove informative for the design of future therapeutic vaccines. However, the human epitope specificity of T cells and the nature of SYMP and ASYMP T cells remain to be determined. We hypothesize that 1) although both SYMP and ASYMP patients recognize most HSV T cell epitopes, there are distinct human T cell epitopes that are recognized mainly by ASYMP individuals or mainly by SYMP patients (9, (13) (14) (15) ; and 2) T cell responses to SYMP epitopes may cause, or at least not protect against, immunopathological recurrent herpetic disease that leads to substantial morbidity, whereas T cell responses to ASYMP epitopes prevent/reduce recurrent herpes disease or cause it to remain subclinical (9, (13) (14) (15) (16) (17) .
The clinical spectrum of HSV-1 and HSV-2 infections, ranging from asymptomatic to frequently distressing symptomatic outbreaks, are associated with HLA class I molecules (18) (19) (20) . These associations suggest that a CD8 + T cell-mediated immune mechanism may influence the outcome of recurrent herpes infection (8) . CD8 + T cells are found in the vicinity of latently infected sensory neurons during subclinical reactivation in mice (21) (22) (23) and in humans (24, 25) . Of many adaptive immune responses explored as correlates of protection against herpes in mice, an overwhelming majority of data suggests that HSV-gBspecific CD8 + T cells contribute to protection (1) (2) (3) (4) (5) . CD8 + T cells, specific to the immunodominant H-2 b -restricted gB [498] [499] [500] [501] [502] [503] [504] [505] epitope, achieve at least partial control of herpetic ocular disease in C57BL/6 mice (8, 12, 26, 27) . We recently reported a negative correlation between dysfunctional HSV-gB 498-505 -specific CD8 + T cells that reside within sensory trigeminal ganglia (i.e., the site of latent infection) and control of HSV-1 reactivation (21, 23) . However, in clinical trials, therapeutic vaccination with a recombinant gB protein, which presumably contains both ASYMP and SYMP epitopes, led only to moderate and transient protection (6) . Considering the wealth of data addressing the mechanism of CD8 + T cell antiviral activity in mice, it is surprising how few reports exist exploring the immune mechanisms of SYMP and ASYMP infection in humans. The immune mechanisms by which HSV-specific asymptomatic CD8 + T cells control herpes disease and HSV-specific symptomatic CD8 + T cells do not remain to be fully elucidated in humans. Identifying these mechanisms, or at least the viral epitopes involved, is critical for a rational design of an effective herpes vaccine. The present study was undertaken to characterize the population size, specificity, and function of CD8 + T cells in HSV-1-seropositive ASYMP versus SYMP patients. Because of the obvious ethical and practical considerations in obtaining tissue-resident CD8 + T cells (i.e., from the cornea or trigeminal ganglia), our investigation was limited to peripheral blood-derived CD8 + T cells.
We found that CD8 + T cells from HLA-A*02:01-positive, HSV-seropositive ASYMP individuals preferentially recognize naturally processed specific epitopes from HSV-1 gB, whereas CD8 + T cells from HLA-A*02:01-positive, HSV-seropositive SYMP patients preferentially recognized other nonoverlapping gB epitopes. The ASYMP epitope-primed CD8 + T cells displayed polyfunctional activity (p < 0.005). They concurrently produced three to five functions, including cytotoxic activity, ability to proliferate, and ability to produce the effector cytokines IL-2, IFN-γ and TNF-α. In contrast, SYMP epitope-primed CD8 + T cells were primarily monofunctional and produced IL-6, IL-8, and IL-17 inflammatory cytokines. Furthermore, immunization of a novel susceptible "humanized" HLA-A*02:01 transgenic mouse model (i.e., on BALB/c genetic background) with ASYMP epitopes, but not with SYMP epitopes, induced a strong CD8 + T cell-dependent protective immunity against ocular herpes infection and disease. Altogether, using a combination of several immunological assays, the results presented in this study characterize the breadth, function, and specificity of a virus-specific CD8 + T cell population that segregates with immunologic control of herpes disease in both ASYMP individuals and in "humanized" HLA-A*02:01 transgenic mice. These preclinical findings 1) further corroborate our hypothesis that although both SYMP and ASYMP patients recognize most HSV T cell epitopes, there are distinct human T cell epitopes that are strongly recognized mainly by ASYMP individuals or mainly by SYMP patients (9, (13) (14) (15) (16) (17) ; and 2) should help guide the development of the next generation of safe and effective T cell-based herpes vaccine in humans.
Materials and Methods

Human study population
During the last decade (i.e., January 2003-January 2013) we have screened a total of 525 individuals for HSV-1 and HSV-2 seropositivity. Among these, a cohort of 207 immunocompetent individuals, with an age range of 18-65 y (median, 32 y), who were seropositive for HSV-1 were enrolled in the current study. Three hundred eighty-five individuals were white, 140 were non-white (African, Asian, Hispanic, and others), 274 were females, and 251 were males. All patients were negative for HIV, hepatitis B virus, and had no history of immunodeficiency. Two hundred eighteen patients were HSV-1-or HSV-1/HSV-2-seropositive, among whom 208 patients were healthy and ASYMP (individuals who have never had any recurrent herpes disease, ocular, genital, or elsewhere, based on their self-report and physician examination; even a single episode of any herpetic disease in their life will exclude the individual from this group). The other 10 remaining patients were defined as HSV-1-seropositive SYMP who suffered frequent and severe recurrent oral and/or orofacial lesions, with two patients having had clinically welldocumented HSK. Signs of recurrent disease in SYMP patients were defined as herpetic lid lesions, herpetic conjunctivitis, dendritic or geographic keratitis, stromal keratitis, and iritis consistent with HSK, with one or more episodes per year for the past 2 y. However, at the time of blood collection, SYMP patients have no recurrent disease (other than corneal scarring) and have had no recurrences during the past 30 d. They have no ocular disease other than HSK, have no history of recurrent genital herpes, are HSV-1-seropositive and HSV-2-seronegative. Because the spectrum of recurrent ocular herpes disease is wide, our emphasis is mainly on the number of recurrent episodes, not on the severity of the recurrent disease. For simplicity, just the extreme cases of SYMP and ASYMP patients are used. Thus, no attempt was made to assign specific T cell epitopes to specific severity of recurrent lesions. Patients are also excluded when they 1) have an active ocular (or elsewhere) herpetic lesion, or had one in the past 30 d; 2) are seropositive for HSV-2; 3) are pregnant or breastfeeding; or 4) ever took acyclovir or related antiviral drugs or any immunosuppressive drugs. SYMP and ASYMP groups were matched for age, gender, serological status, and race. Sixty-nine healthy control individuals were seronegative for both HSV-1 and HSV-2 and had no history of ocular HSK, genital lesions, or orofacial herpes disease. All subjects were enrolled at the University of California Irvine under approved Institutional Review Board-approved protocols (nos. 2003-3111 and 2009-6963). Written informed consent was received from all participants prior to inclusion in the study.
Bioinformatics analyses
HSV-1 gB open reading frames used in this study were from strain 17 (National Center for Biotechnology Information, accession no. NC-001806). Candidate HLA-A*02:01-restricted epitopes were identified using previously described software from the National Institutes of Health Bioinformatics and Molecular Analysis Section (Washington, DC; http:// bimas.dcrt.nih.gov/molbio/hla_bind/) and the SYFPEITHI algorithm (http:// www.syfpeithi.de/) (3). Potential cleavage sites for human proteasome were identified using NetChop 3.0 (http://www.cbs.dtu.dk/services/NetChop/) (3). MHC Pathway (http:// www.mhc-pathway.net) was also employed in this screening (3) .
Peptide synthesis
Based on the bioinformatics analysis, 10 putative HLA-A*02:01-binding peptides from gB with high estimated t 1/2 of dissociation were synthesized by Magenex (San Diego, CA) on a 9050 Pep Synthesizer using solid-phase peptide synthesis and standard 9-fluorenylmethoxycarbonyl technology (PE Applied Biosystems, Foster City, CA). The purity of peptides was between 75 and 96%, as determined by reversed-phase HPLC (Vydac C18) and mass spectroscopy (Voyager MALDI-TOF system). Stock solutions were made at 1 mg/ml in 10% DMSO in PBS. All peptides were aliquoted and stored at −20°C until assayed.
Binding with soluble HLA-A*02:01 molecules
Quantitative assays to measure binding of peptides to soluble HLA-A*02:01 molecules are based on inhibition of binding of a radiolabeled standard peptide, as recently described (28) . Briefly, 1-10 nM radiolabeled peptide was coincubated with 1 M-1 nM purified MHC and 1-3 µM human β 2 -microglobulin. After 2 d, binding of radiolabeled peptide to MHC class I molecules was determined by capturing MHC/peptide complexes on Greiner Lumitrac 600 microplates coated with W6/32 Ab and measuring bound counts per minutes using a TopCount microscintillation counter. Concentration of peptide yielding 50% inhibition of binding of radiolabeled probe peptide (IC 50 ) was then calculated. To determine whether synthetic peptides could stabilize HLA-A*02:01 molecule expression on the T 2 cell surface, peptide-inducing HLA-A*02:01 upregulation on T 2 cells was examined according to a previously described protocol (3). T 2 cells (3 × 10 5 /well) were incubated with different concentrations of individual gB peptide (as indicated in Fig. 2B ) in 48-well plates for 18 h at 26°C. Cells were then incubated at 37°C for 3 h in the presence of human β 2 -microglobulin (1 µg/ml) and BD GolgiStop (5 µg/ml) to block cell surface expression of newly synthesized HLA-A*02:01 molecules. The cells were washed with FACS buffer (1% BSA and 0.1% sodium azide in PBS) and stained with anti-HLA-A2.1-specific mAb BB7.2 (BD Pharmingen, San Diego, CA) at 4°C for 30 min. After incubation, the cells were washed with FACS buffer, fixed with 1% paraformaldehyde in PBS, and analyzed by flow cytometry using a BD LSR II (Becton Dickinson, Mountain View, CA). The acquired data, including mean fluorescence intensity (MFI), were analyzed with a FlowJo software version 9.5.2 (Tree Star). Percentage MFI increase was calculated as [(MFI with the given peptide − MFI without peptide)/(MFI without peptide)] × 100. Each experiment was performed three times, and means ± SD were calculated.
HLA typing
HLA-A2 subtyping was performed using a commercial sequence-specific primer kit (SSPR1-A2; One Lambda, Canoga Park, CA) following the manufacturer's instructions (29) . Briefly, genomic DNA extracted from PBMCs of HSV-seropositive SYMP and ASYMP individuals was analyzed using a Tecan DNA workstation from a 96-well plate with 2 µl volume per well, as previously described (29) . The yield and purity of each DNA sample were tested using a UV spectrophotometer. The integrity of DNA samples was ascertained by electrophoresis on agarose gel. Each DNA sample was then subjected to multiple small volume PCR reactions using primers specific to areas of the genome surrounding the single point mutations associated with each allele. Only primers that matched the specific sequence of a particular allele would amplify a product. The PCR products were subsequently electrophoresed on a 2.5% agarose gel with ethidium bromide, and the pattern of amplicon generation was analyzed using HLA Fusion software (One Lambda). Additionally, the HLA-A2 status was confirmed by staining PBMCs with 2 µl anti-HLA-A2 mAb BB7.2 (BD Pharmingen) at 4°C for 30 min. The cells were washed, acquired on a BD LSR II, and analyzed using FlowJo software version 9.5.2 (Tree Star).
PBMC isolation
Healthy individuals (negative for HIV, hepatitis B virus, and with or without any HSV infection history) were recruited at the University of California Irvine Institute for Clinical and Translational Science. Between 40 and 100 ml blood was drawn into yellow-top Vacutainer tubes (Becton Dickinson). The serum was isolated and stored at −80°C for detection of anti-HSV-1 and anti-HSV-2 Abs, as we previously described (9) . PBMCs were isolated by gradient centrifugation using leukocyte separation medium (Cellgro, Manassas, VA). The cells were washed in PBS and resuspended in complete culture medium consisting of RPMI 1640 medium containing 10% FBS (Gemini Bio-Products, Woodland, CA) supplemented with 1× penicillin/L-glutamine/streptomycin, 1× sodium pyruvate, 1× nonessential amino acids, and 50 µM 2-ME (Life Technologies, Rockville, MD). Aliquots of freshly isolated PBMCs were also cryopreserved in 90% FCS and 10% DMSO in liquid nitrogen for future testing.
T cell proliferation assay
CD8 + T cell proliferation was measured using a CFSE assay as we recently described (2) . Briefly, PBMCs were labeled with CFSE (2 µM) and incubated for 5 d with or without individual gB peptide (10 µg/ml). As a positive control, 2 µg/ml PHA was used to stimulate T cells for 3 d. The cells were then washed and stained with PE-conjugated mAbs specific to human CD8 molecules (clone HIT8A; BD Pharmingen). The numbers of dividing CD8 + T cells per 300,000 total cells were analyzed by FACS. Their absolute number was calculated using the following formula: number of events in CD8 + /CFSE + cells × number of events in gated lymphocytes/number of total events acquired.
Flow cytometry analysis
For each stimulation condition, at least 500,000 total events were acquired on a BD LSR II, and data analysis was performed using FlowJo version 9.5.2 (Tree Star). PBMCs were analyzed by flow cytometry after staining with fluorochrome-conjugated human specific mAbs. FITC-conjugated CD8 (clone HIT8A) and FITC-conjugated HLA-A2 (clone BB7.2) were purchased from BD Pharmingen. PE-conjugated gB peptide/tetramer complexes were gifted by the National Institutes of Health Tetramer Facility. A total of 10 6 PBMCs were stained in PBS containing 1% BSA and 0.1% sodium azide (FACS buffer) for 45 min at 4°C followed by three washes in FACS buffer and fixed in 1% paraformaldehyde. The gating strategy was similar to that used in our previous work (3) . Briefly, we gated on single cells, dump − cells, viable cells (aqua blue − ), lymphocytes, CD3 + cells, and CD8 + cells before finally gating on functional cells. Reported data have been corrected for background based on the negative (no peptide) control where appropriate, and only responses with a total frequency >0.10% of total CD8 + T cells (after background subtraction) were considered to be positive responses.
Tetramer/gB peptide complexes staining
Fresh PBMCs were analyzed for the frequency of CD8 + T cells recognizing the gB peptide/ tetramer complexes, as we previously described (12, 30) . The cells were incubated with gB peptide/tetramer complex for 30-45 min at 37°C. The cell preparations were then washed with FACS buffer and stained with FITC-conjugated anti-human CD8 mAb (BD Pharmingen). The cells were washed and fixed with 1% paraformaldehyde in PBS. The cells were then acquired on a BD LSR II and data were analyzed using FlowJo version 9.5.2 (Tree Star).
IFN-γ-ELISPOT assays
gB-specific IFN-γ-producing CD8 + T cells were characterized using ELISPOT. T cell stimulation was measured by IFN-γ production in peptide-stimulated PBMCs using a BD IFN-γ-ELISPOT kit (BD Pharmingen). Briefly, 5 × 10 5 PBMCs were stimulated with 20 µM individual gB peptides for 5 d. Then, activated PBMCs were harvested, washed, and restimulated with the gB peptides for 24 h in IFN-γ-ELISPOT plates (Millipore) that had been previously coated with anti-human IFN-γ capture Ab in a humidified incubator at 37°C with 5% CO 2 . The spot-forming cells were developed as described by the manufacturer (BD IFN-γ-ELISPOT kit; BD Pharmingen) and counted under stereoscopic microscope. Average spot counts for duplicate wells were calculated and background from wells with cells in medium only was subtracted.
Multiplex cytokine array
Fresh PBMCs (5 × 10 5 cells) were stimulated in a 96-well round-bottom plate with or without gB peptides for 24, 48, or 96 h. Supernatants were collected after 24, 48, or 96 h of stimulation. Production of six different cytokines (IL-2, IL-6, IL-8, IL-17, IFN-γ, and TNF-α) was assayed using multiplex cytokine arrays (BioLegend) per the manufacturer's protocols. Samples were acquired on a Labscan 100 analyzer (Luminex) using Bio-Plex manager 6.0 software (Bio-Rad). Background levels were determined from nonstimulated PBMCs.
CD107 cytotoxicity assay
To detect cytolytic CD8 + T cells recognizing gB peptides in freshly activated and in vitroactivated PBMCs, we performed CD107a/b cytotoxicity assay. Betts and colleagues (31, 32) have described the CD107 assay as an alternative cytotoxicity assay that is able to address some of the shortcomings of the 51 Cr-release assay. The CD107 assay was performed as described (33, 34 ) with a few modifications. On the day of the assay, nonstimulated or in vitro gB peptide-stimulated PBMCs were incubated at 37°C for 6 h in a 96-well plate with BD GolgiStop (BD Biosciences), costimulatory anti-CD28 and anti-CD49d Abs (1 µg/ml), and 10 µl CD107a-FITC and CD107b-FITC. At the end of the incubation period the cells were harvested into separate tubes and washed twice with FACS buffer then stained with PE-conjugated anti-human CD8 for 30 min at 4°C. The cells were then washed again, fixed, and 500,000 total events were acquired on a BD LSR II, and data analysis was performed using FlowJo version 9.5.2 (Tree Star). 
HLA-
Virus production
HSV-1 (strain McKrae) was used in this study (3) and was grown and titrated on rabbit skin (RS) cells. UV-inactivated HSV-1 was generated as we previously described (1). HSV inactivation was confirmed by the inability to produce plaques when tested on RS cells.
Immunization of "humanized" HLA transgenic mice with SYMP and ASYMP peptide epitopes and ocular herpes challenge
Three groups of age-matched female HLA-A*02:01 transgenic mice (n = 10 each) were immunized s.c. with the ASYMP CD8 + T cell human epitopes (gB 342-350 and gB 561-569 ) delivered with the CD4 + T cell PADRE epitope emulsified in CpG 1826 adjuvant (ASYMP), with the SYMP CD8 + T cell human epitopes (gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB [441] [442] [443] [444] [445] [446] [447] [448] [449] ) delivered with the CD4 + T cell PADRE epitope emulsified in CpG 1826 adjuvant (SYMP), or with the CpG 1826 adjuvant alone (mock) on days 0 and day 21. All immunizations were carried out with 100 µM each peptide. A preliminary experiment was conducted to determine the LD 50 of strain McKrae in naive HLA-A*02:01 transgenic mice following ocular challenge. Two × LD 50 was then used in peptide-and mock-immunized mice to determine the protective efficacy of SYMP and ASYMP epitopes against lethal ocular herpes infection and disease. Two weeks after the final immunization, mice received an ocular HSV-1 challenge with 2 × 10 5 PFU (strain McKrae). The corneas were inoculated, without scarification, with the virus in a 4 µl tissue culture medium placed gently and topically on the corneas of immunized and control mice, as previously described (3). Control mice were inoculated using mock samples of virus.
Monitoring of ocular herpes infection and disease
Animals were examined for signs of ocular disease by slit lamp. Clinical assessments were made immediately before inoculation and on days 1, 4, 7, 10, 14, and 21 thereafter. The examination was performed by investigators blinded to the treatment regimen of the mice and scored according to a standard 0-4 scale: 0, no disease; 1, 25%; 2, 50%; 3, 75%; and 4, 100% staining, as previously described (3). To quantify replication and clearance of HSV-1 from the eyes, mice were swabbed daily with moist, type 1 calcium alginate swabs. Swabs were placed in 1.0 ml titration media (Media 199, 2% penicillin/streptomycin, 2% newborn calf serum) and frozen at −80°C until titrated on RS cell monolayers as described previously (3). Mice were also examined for survival in a window of 30 d after challenge, as we previously described (3).
Statistical analyses
Data for each assay were compared by ANOVA and a Student t test using GraphPad Prism 5 software (GraphPad Software, San Diego, CA). Differences between the groups were identified by ANOVA and multiple comparison procedures, as we previously described (35) . Data are expressed as the means ± SD. Results were considered to be statistically significant at p < 0.05.
Results
In silico prediction of potential HLA-A*02:01-restricted T cell epitopes from HSV-1 gB Ag
We have searched the deduced HSV-1 (strain 17) gB amino acid sequence for potential HLA-A*02:01-binding regions using BIMAS, SYFPEITHI, and MAPPP predictive computational algorithms. Based on these analyses, we selected 10 potential peptide epitopes with high predicted affinity to the HLA-A*02:01 molecule, a haplotype that is represented in >50% of the world human population, irrespective of gender and ethnicity (2) ( Table I) . Nine of the 10 gB peptide epitopes shared the HLA-A*02:01-binding motifs: leucine, isoleucine, or methionine at the second position and a valine, leucine, isoleucine, or threonine at the ninth position. As confirmed by the MHCPred computational algorithm, all 10 gB peptides that bear putative antigenic and immunogenic HLA-A*02:01-binding CD8 + T cell epitopes are more readily accessible to proteolysis, an event that precedes T cell epitope presentation in association with HLA molecules (2, 3). The 10 potential epitopes are not confined to a particular region of gB (Fig. 1) . One of the 10 predicted epitopes, gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , is located within the gB signal sequence. Seven belong to the external N-terminal ectodomain portion of gB (gB 161-169 , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 286-294 , gB 342-350 , gB 343-351 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB [447] [448] [449] [450] [451] [452] [453] [454] [455] ). Two are adjacent to the hydrophobic membrane transmembrane anchor domain (gB 561-569 and gB [675] [676] [677] [678] [679] [680] [681] [682] [683] ). None of the predicted peptides is within the transmembrane or the C-terminal intracellular domain and none belongs to known glycosylated regions of gB protein.
Six of 10 potential gB epitope peptides bind with high affinity to HLA-A*02:01 and stabilize its expression on the surface of target cells Peptides corresponding to the 10 highest probability gB epitopes, described above, were synthesized and the binding affinity of each peptide to soluble purified HLA-A*02:01 molecules was tested using a quantitative assay based on competitive inhibition of the binding of a radiolabeled reference peptide (2, 3). Six of 10 gB peptide epitopes bound with high affinity to the soluble HLA-A*02:01 molecules with a K d of <100 nM ( Fig. 2A) . Specifically, gB [17] [18] [19] [20] [21] [22] [23] [24] [25] In a subsequent experiment, peptides corresponding to the 10 gB epitopes were used to perform a stabilization assay of HLA-A*02:01 molecules on the cell membrane of T 2 cells (a class I-HLA-transfected B × T hybrid cell line). This assay used a mAb specific to a folded structure of HLA-A*02:01 to estimate in a FACS assay the relative amount of HLA-A*02:01 molecules retained on the surface of T 2 cells following incubation with a potential peptide epitope (3). The amount of empty HLA-A*02:01 molecules retained on the surface of T 2 cells is normally at a low level. Each gB peptide was tested individually at four descending concentrations: 20, 10, 5, and 2. Collectively, these results indicate that, under these conditions, gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB 161-169 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , gB [447] [448] [449] [450] [451] [452] [453] [454] [455] , gB 561-569 , and gB 675-683 bind with high affinity to HLA-A*02:01 and stabilize its expression on the surface of target cells. Because binding affinity of an epitope peptide may not always reflect its efficient presentation to T cells or predict its ability to stimulate T cells, we next used a combination of several immunological assays to assess the ability of each of the 10 gB peptides to recall functional HSV-specific CD8 + T cells in HSV-1-seropositive individuals. CD8 + T cell responses specific to each gB peptide epitope described above were studied in HLA-A*02:01-positive, HSV-seropositive individuals. HLA-A*02:01-positive, HSV-seronegative individuals were used as controls. The characteristics of our study population with respect to gender, age, HSV-1 and HSV-2 seropositivity, and HLA-A*02:01 frequency distribution are detailed in Materials and Methods. Briefly, during a period of 10 y, 525 immunocompetent individuals, with an age range of 18-65 y (median, 32 y) who were seropositive or seronegative for HSV-1 and/or HSV-2, were enrolled in the study. Among HSV-seropositive individuals, 207 were HSV-1-seropositive and HSV-2-seronegative, 238 were HSV-2-seropositive and HSV-1-seronegative, and 11 individuals were both HSV-1-and HSV-2-seropositive. Because HSV-1 is the principal cause of ocular herpetic disease, this study focused solely on individuals who are HSV-1-seropositive and HSV-2-seronegative.
We first determined the frequency of CD8 + T cells specific to each of the 10 gB peptides in HSV-1-seropositive individuals using peptide/PE-labeled HLA-A*02:01 tetramers together with FITC-conjugated mAb specific to human CD8 + T cells (Fig. 3A) . After peptide in vitro stimulation, we detected significantly higher percentages of tetramer + CD8 + T cells specific to 5 of 10 peptides: gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] Because the frequency of CD8 + T cells specific to a given epitope may not always reflect their functionality, we next determined the ability of each of the 10 gB epitope peptides to recall proliferative and IFN-γ-producing epitope-specific CD8 + T cells in HLA-A*02:01-positive, HSV-1-seropositive individuals. HLA-A*02:01-positive, HSV-seronegative individuals were used as negative controls. CD8 + T cells were isolated from fresh peripheral blood of each group and stimulated for 5 d with individual gB peptides, and the number of epitope-specific IFN-γ-producing CD8 + T cells was determined by a 24-h ELISPOT assay. Our previous analysis revealed that 10 or more spots per 10 5 CD8 + T cells gave a 99.5% probability for defining a positive response and 10 spot-forming cells per 10 5 CD8 + T cells was therefore used as the cutoff point (1, 9). Significant IFN-γ-producing CD8 + T cell responses specific to 6 of 10 peptides, gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB 161-169 , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 342-350 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB 561-569 were detected in HLA-A*02:01-positive, HSV-1-seropositive individuals (p < 0.005; Fig. 3C, 3E ). In comparison, <10% of individuals showed positive T cell responses to the remaining four peptides (gB 286-294 , gB 343-351 , gB [447] [448] [449] [450] [451] [452] [453] [454] [455] , and gB 675-683 ). Of note, significant IFN-γ-producing CD8 + T cell response specific to the gB 161-169 epitope was detected regardless of the low frequency of CD8 + T cells detected in HLA-A*02:01-positive, HSV-seropositive individuals (Fig. 3A, 3B) . No significant IFN-γ-producing CD8 + T cell responses specific to any of the 10 gB epitopes were detected in HLA-A*02:01-positive, HSV-seronegative healthy controls.
Because lack of IFN-γ production by T cells may not always reflect lack of a T cell response (12, 35) , we also studied the proliferative responses of CD8 + T cells from HSV-1-seropositive individuals labeled with CFSE and restimulated in vitro with each of the 10 gB peptides. The cells were stained with anti-human CD8-PE, and the number of dividing CD8 + T cells among a total number of 300,000 cells was determined by FACS, as we previously described (3). Briefly, gated CFSE + CD8 + T cells from HLAA*02:01-positive, HSV-1-seropositive individuals were examined for proliferation. As shown in Fig. 3D , gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB 161-169 , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 286-294 , gB 342-350 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB 561-569 peptide epitopes all induced significant CD8 + T cell proliferative responses in HLA-A*02:01-positive, HSV-1-seropositive individuals (p < 0.005). All but gB 286-294 epitopes were positive in the tetramer and ELISPOT assay above. As expected, no proliferative HSV-gB epitope-specific CD8 + T cell responses were detected in HLA-A*02:01-positive, HSV-seronegative controls (not shown).
Altogether, the HLA binding and the three immunological assays described above (tetramer frequency, IFN-γ production, and CFSE proliferation) point to gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 342-350 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB 561-569 as functional immunodominant gB epitopes that specifically recall frequent CD8 + T cells in HLA-A*02:01-positive, HSV-1-seropositive individuals.
Frequent IFN-γ-producing CD8 + T cells specific to immunodominant gB 342-350 and gB 561-569 epitopes detected in asymptomatic individuals
We next asked whether there was a difference in the frequency and function of CD8 + T cells specific to gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 342-350 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB 561-569 epitopes between HSVseropositive SYMP and ASYMP individuals. The characteristics of the SYMP and ASYMP study populations used in this study with regard to HSV seropositivity and disease are described in detail in Materials and Methods. Briefly, among the HSV-1-seropositive population, 208 individuals are clinically healthy with no apparent, or history of, ocular, genital, or labial herpes lesions, and these are designated as ASYMP (no history of recurrent HSV disease). Ten patients were identified as HSV-1-seropositive, HSV-2-seronegative SYMP who had a clinically well-documented history of HSV-1 recurrent ocular disease (rHSK) such as herpetic lid lesions, herpetic conjunctivitis, dendritic or geographic keratitis, stromal keratitis, and iritis consistent with rHSK, with one or more episodes per year for the past 2 y.
We first compared the ability of all 10 potential gB epitopes to recall functional CD8 + T cells in 10 HLA-A*02:01-positive, HSV-1-seropositive ASYMP and 10 HLA-A*02:01-positive, HSV-1-seropositive SYMP individuals. CD8 + T cells, isolated from fresh peripheral blood in each group, were stimulated for 5 d with individual gB peptides and the number of gB-epitope-specific IFN-γ-producing CD8 + T cells was determined in a 24-h ELISPOT assay. As shown in Fig. 4A , 2 of 10 peptides, gB 342-350 and gB 561-569 , induced significantly higher IFN-γ-producing CD8 + T cells from 10 sequentially studied HLA-A*02:01-positive, HSV-1-seropositive ASYMP healthy individuals as compared with 10 SYMP individuals, suggesting that those two epitopes are ASYMP epitopes (p < 0.005). In contrast, gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 441-449 peptides appeared to induce significantly higher IFN-γ-producing CD8 + T cells preferentially from SYMP individuals compared with ASYMP individuals, suggesting that those two epitopes are SYMP epitopes (p < 0.005). The gB [17] [18] [19] [20] [21] [22] [23] [24] [25] and gB 286-294 peptides appeared to induce significantly higher IFN-γ-producing CD8 + T cells in both SYMP and ASYMP individuals.
We then extended our analysis to assess the frequency of circulating CD8 + T cells, specific to each of the five immunodominant gB epitopes described above (gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 342-350 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB 561-569 ), in PBMCs isolated from five ASYMP and five SYMP individuals. The subdominant epitope gB 675-683 was used as control. To obtain an objective enumeration of gB epitope-specific CD8 + T cells, each tetramer was tested at three or four dilutions and the numbers (instead of percentage) of epitope-specific CD8 + T cells per 100,000 T cells were determined. Significantly more tetramer + CD8 + T cells specific to gB 342-350 and gB 561-569 epitopes were detected in ASYMP individuals, confirming these as ASYMP epitopes (p < 0.005; Fig. 4B, 4C ). In contrast, significantly higher numbers of tetramer + CD8 + T cells specific to gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 441-449 epitopes were detected in SYMP individuals (p < 0.005; Fig. 4B, 4C ), suggesting these as SYMP epitopes.
Asymptomatic gB epitope-specific CD8 + T cells displayed concurrent polyfunctional activities and were capable of recognizing naturally processed epitopes on HSV-1-infected target cells
We examined the cytotoxic function of CD8 + T cells from SYMP and ASYMP individuals. CD107a and CD107b are lysosomal-associated membrane glycoproteins that surround the core of the lytic granules in cytotoxic T cells (CTLs) (31, 32) . Upon TCR engagement and stimulation by Ags in association with MHC molecules, CD107a/b are exposed on the cell membrane of cytotoxic T cells. Thus, the level of CD107a/b expression on the surface of CTLs is used as a direct assay for the epitope-specific CTL response (31) . To assess whether gB epitope-specific CD8 + T cells display CTL activity, fresh PBMC-derived CD8 + T cell lines were generated from HLA-A The results indicate that ASYMP epitope-induced CD8 + T cells have cytotoxic activity against HSV-1-infected cells and are able to specifically recognize endogenously processed gB epitopes from both HSV-1-and VVgB-infected target cells. There was no CTL response against any peptides in individuals that were seronegative for HSV regardless of whether they were HLA-A*02:01-positive or HLA-A*02:01-negative (data not shown).
The levels of six different inflammatory cytokines (IL-2, IL-6, IL-8, IL-17, IFN-γ , and TNF-α) produced by CD8 + T cells from ASYMP versus SYMP individuals following in vitro restimulation with UV-inactivated HSV-1 (strain McKrae) were compared by the Luminex microbeads system. As shown in Fig. 5B , CD8 + T cells from SYMP patients produced high levels of IL-6, IL-8, and IL-17 (black-filled portion of the pie chart), consistent with differentiated inflammatory T cells. In contrast, T cells from ASYMP individuals produced more of the effector cytokines IL-2, IFN-γ, and TNF-α (black-filled portion of the pie chart). Fig. 5C summarizes the percentage of ASYMP and SYMP individuals who showed positive results for one or several CD8 + T cell functions following in vitro restimulation with either ASYMP or SYMP gB peptides. Overall, 95% of ASYMP individuals had HSV-specific CD8 + T cells with three to five functions, indicating their ability to maintain greater frequencies and display concurrent polyfunctional activities: 1) production of high levels of lytic granules upon TCR engagement (CD107a/b cytotoxic activity); 2) expression of IFN-γ (ELISPOT); 3) high proliferation (CFSE); 4) production of high levels of IL-2, IFN-γ, and TNF-α effector cytokines (or proinflammatory cytokines in the case of SYMP individuals); and 5) tetramer frequency (p < 0.005). In contrast, only 32% of SYMP individuals had HSV-specific CD8 + T cells with three to five functions whereas most had just one function, suggesting that CD8 + T cells from SYMP patients tended to be monofunctional and produced more inflammatory cytokines (p < 0.005). Finally, similar levels of HLA-A*02:01 expression were detected by FACS on the surface of APCs (both dendritic cells and macrophages) derived from SYMP and ASYMP individuals (Fig. 5D ). This result suggests that the apparent polyfunctionality of CD8 + T cells detected in ASYMP individuals is not a result of a high level of expression of HLA-A0201 molecules on their APCs, but rather to an intrinsic multifunctionality of CD8 + T cells specific to ASYMP epitopes.
Collectively, the results indicate that 1) a particular breadth and specificity of virus-specific CD8 + T cell responses is associated with control of herpes disease, and 2) HSV-specific CD8 + T cells from ASYMP individuals displayed concurrent polyfunctional activities whereas CD8 + T cells from SYMP patients tended to be monofunctional.
Immunization with asymptomatic epitopes induced a CD8 + T cell-dependent protective immunity against ocular herpes in "humanized" HLA-A*02:01 transgenic mice
Because the in vitro antigenicity of CD8 + T cell epitopes may not always translate into functional in vivo immunogenicity, we next set up a preclinical vaccine trial using SYMP and ASYMP epitopes in a novel humanized HLA-A*02:01 transgenic mouse model.
To evaluate whether immunization with ASYMP CD8 + T cell epitopes confer any protection against ocular herpes, groups of susceptible HLA-A*02:01 transgenic humanized mice (n = 10 mice/group, BALB/c genetic background) were immunized s.c. twice, 21 d apart with the two ASYMP CD8 + T cell epitopes gB 342-350 and gB 561-569 (group 1) or with SYMP epitopes, gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 441-449 (group 2). These were delivered together with the CD4 + T helper PADRE epitope and emulsified in CpG 1826 adjuvant. As negative control, mock-immunized mice received adjuvant alone (group 3). Two weeks after the second and final immunization, animals from all groups received an ocular HSV-1 challenge (2 × 10 5 PFU, McKrae strain). Of note, the sequences of both SYMP and ASYMP epitopes are highly conserved between HSV-1 and HSV-2 strains (Table II) ; however, no significant homology exists between the amino acid sequences of the 10 HSV-1 gB T cell epitopes studied and the gB amino acid sequences of varicella zoster virus, EBV, and CMV (Table  II) . The pathology clinical scores observed in the ASYMP group were significantly lower than those observed in the SYMP group and the mock-immunized group (p = 0.001 for all; Fig. 6A ). Furthermore, significantly lower viral loads were detected on day 7 postinfection in eye swabs of the ASYMP group compared with the SYMP and mock-immunized groups (p = 0.01; Fig. 6B ). All animals in the ASYMP group survived lethal infection (100%) compared with only 40% survival in the SYMP group and 0% in the mock-immunized group (p < 0.005; Fig. 6C ). Overall, there was a positive correlation between survival and the number of ASYMP CD8 + T cells detected in the draining lymph node (Fig. 6D , p < 0.005, r 2 = 0.7996, 95% confidence interval). Similar to what has been observed in ASYMP individuals, cultured CD8 + T cells from ASYMP-immunized mice had significantly higher proportions of cells with simultaneous expression of three to five functions, whereas SYMPimmunized mice had few or no detectable cells expressing more than three functions simultaneously (75.5 and 17.5%, respectively; p = 0.005; not shown). To verify the involvement of CD8 + T cells in the observed protection induced following immunization with the ASYMP CD8 + T cell epitopes, we performed an in vivo depletion of either CD4 + or CD8 + T cells in immunized mice before virus challenge using specific mAbs. As shown in Fig. 6E , depletion of CD8 + T cells, but not of CD4 + T cells, significantly abrogated protection against death induced by immunization with the ASYMP CD8 + T cell epitopes (p < 0.005), suggesting that CD8 + T cells, but not CD4 + T cells, were required for protection against lethal ocular herpes.
Altogether, these results indicate that immunization with ASYMP CD8 + T cell epitopes, but not with SYMP epitopes, decreased ocular herpes disease, decreased virus replication, and protected against lethal ocular herpes in susceptible HLA transgenic mice.
Discussion
In the present study, we compared the population size, specificity, and function of HSVspecific CD8 + T cells from ASYMP and SYMP patients (i.e., those who did not show recurrent HSV disease episodes versus those that did, respectively). Striking quantitative and qualitative differences were found between CD8 + T cells from HSV-seropositive ASYMP individuals, who manage to immunologically control herpetic disease to clinically undetectable levels, and CD8 + T cells from SYMP patients, who failed to prevent recurrent herpetic disease. We identified two ASYMP CD8 + epitopes from HSV-1 gB that were preferentially recognized by CD8 + T cells from "protected" ASYMP individuals. Immunization with these ASYMP epitopes, gB 342-350 and gB 561-569 , induced high protection against herpes infection and disease in humanized HLA transgenic mice. In contrast, two nonoverlapping epitopes, gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , that were preferentially recognized by CD8 + T cells from SYMP individuals produced little protection.
Rather than just using a few in vitro predictive assays to map CD8 + epitopes, we used several computational algorithms followed by both in vitro and in vivo functional immunological assays. High-performing predictive computational algorithms have been available for more than a decade; however, their value in terms of actual epitope binding has only been extensively studied more recently (28, 36, 37) . Many immunological assays have been developed to validate computationally predicted human CD8 + T cell epitopes, including binding affinity to purified HLA molecules, tetramer assays, cell membrane HLA stabilization assays, CD8 + T cell cytokine analysis, and CFSE proliferation assays (28, 38, 39) . When used individually, each screen is not sufficient to conclusively identify functional CD8 + T cell epitopes (27, 28, 38, 40) . However, combinations of these screens can provide strong evidence of functional epitopes (3, 28, 33) . In this study, we supported our predictive computational algorithms with immunological results, including in vitro assays of cell surface stabilization of HLA-A*02:01 molecules on T 2 cells, functional ex vivo and in vitro CD8 + T cells assays, and tetramer staining of CD8 + T cells. Using these multiple screens we identified four high-affinity gB epitopes that were naturally processed and able to recall frequent functional human CD8 + T cells in vitro. Of interest is that the gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB [342] [343] [344] [345] [346] [347] [348] [349] [350] peptides that appeared to bind with only low affinity to HLA-A*02:01 molecules in vitro still induced a strong expansion of CD8 + T cell response in vitro. Although the reason for this is not completely understood, this result highlights the importance of screening potential peptide epitopes using multiple immunological assays.
The in vivo immunogenicity and protective efficacy of human T cell epitopes found to be antigenic in vitro is crucial in vaccine design (34, (41) (42) (43) . Only two of four immunodominant gB epitopes were found in this study to be immunogenic and protective in humanized HLA transgenic mice. This suggests that up to 50% of human CD8 + epitopes recently reported as recognized by human CD8 + T cells in vitro may not be as functionally immunogenic and protective as might be expected (8, 9, 24, (44) (45) (46) . Additionally, some of the HSV-1 human T cell epitopes may actually be pathogenic and contribute to exacerbation of disease as we recently found for an HLA-A*02:01-restricted CD8 + T cell epitope from HSV-1 gK (47). Because our approach to epitope identification in this study was tailored specifically for HLA-A*02:01-restricted epitopes, the results reported are not to imply that these are the only human CD8 + T cell epitopes present on gB. However, this study describes a model system that could be applied to any HLA class I haplotype and to any other herpes structural or regulatory proteins to identify symptomatic versus asymptomatic epitopes.
To gain more insight into the nature of CD8 + T cell populations that are predominant in SYMP versus ASYMP individuals, we used several immunological assays to determine the population size, as well as the specificity and the function of CD8 + T cells obtained from peripheral blood. Although we are aware that information gained from peripheral blood T cells may not be completely reflective of tissue-resident T cells, because of the obvious ethical and practical considerations of obtaining tissue-resident CD8 + T cells (i.e., from the cornea or from trigeminal ganglia, the site of latent infection), our investigations were limited to PBMC-derived CD8 + T cells. A comparison of CD8 + T cell responses in vitro versus ex vivo points to a similar pattern and hierarchy of immunodominance of HSV-1 gB epitope-specific CD8 + T cell responses in ASYMP and SYMP individuals: 1) the most frequent, robust, and polyfunctional CD8 + T cell responses in ASYMP individuals were directed mainly against gB 342-350 and gB 561-569 epitopes; 2) in contrast, the most frequent, robust CD8 + T cell responses in SYMP individuals were directed mainly against gB [183] [184] [185] [186] [187] [188] [189] [190] [191] and gB 441-449 epitopes. Hence, peptide enrichment of PBMC-derived CD8 + T cells did not appear to introduce an in vitro culture bias or to change the main conclusions of the present study. Besides, it is well known that peptide epitope boosting of T cells in vitro, in situations of low CD8 + T cell frequencies such as during latent herpes infection, may potentially enrich PBMC-derived T cells (3, 24, 45) . Thus, as expected, the magnitudes of HSVspecific CD8 + T cell responses were much higher than ex vivo responses, when PBMCderived T cells were restimulated in vitro with gB peptide epitopes. Under the above circumstances, HSV-specific CD8 + T cells from ASYMP patients had a greater frequency of "polyfunctionality". Of ASYMP individuals tested, 95.5% had CD8 + T cells able to produce three to five functions concurrently-namely 1) CD107a/b cytotoxic activity; 1) expression of IFN-γ (ELISPOT); 3) high proliferation (CFSE); 4) high levels of IL-2, IFN-γ, and TNF-α effector cytokines (or proinflammatory cytokines in the case of SYMP individuals); and 5) tetramer frequency-compared with only 32% of SYMP individuals. Thus, CD8 + T cells from ASYMP individuals tended to be polyfunctional, whereas those from SYMP individuals tended to be monofunctional.
Phenotypic and functional characterization of various subsets of effector and central memory CD8 + T cells in SYMP and ASYMP individuals is certainly an important goal, but it remains beyond the scope of the present study, which focuses mainly on comparing epitope specificities and function of CD8 + T cells in SYMP versus ASYMP individuals. Studies of characterization of HSV-specific memory CD8 + T cell subsets in SYMP and ASYMP individuals, using tetramers and CD44, CCR7, and CD62L markers, are currently being conducted in our laboratory. Detailed results of those studies, which overall point to SYMP epitope-specific CD8 + T cells are mainly of the central memory phenotype, whereas ASYMP epitope-specific CD8 + T cells are mainly of the effector memory phenotype, will be the subject of future studies. Nevertheless, as illustrated in Fig. 7 , both direct and indirect mechanisms might be involved in ASYMP CD8 + T cell-mediated protection and in SYMP CD8 + T cell-mediated susceptibility to recurrent herpetic disease. The polyfunctionality of ASYMP CD8 + T cells segregated with immunologic control of herpes infection and disease in both ASYMP individuals and humanized HLA transgenic mice. Thus, polyfunctionality of HSV-specific CD8 + T cells is likely to be an important mechanism accounting for the immunologic control of herpes. Symptomatic CD8 + T cells may be directly involved in the appearance and/or exacerbation of recurrent immunopathologic corneal disease. This could occur through inflammatory cytokines. This mechanism is supported by the functional characterization of the CD8 + T cells from SYMP patients that produced inflammatory cytokines (IL-6, IL-8, and IL-17) compared with those from ASYMP individuals. ASYMP epitope-specific CD8 + T cell lines from ASYMP individuals appeared to recognize naturally processed epitopes on HSV-1-infected cells and had strong virus inhibitory cytotoxic activity. The ultimate underlying molecular mechanism by which CD8 + T cells contribute to the maintenance of the asymptomatic state is not defined by the present study. However, the findings are consistent with a potential role of CD8 + T cells specific to ASYMP epitopes as "protective" and of CD8 + T cells specific to SYMP epitopes as "nonprotective" or even as "pathogenic." A formal demonstration that ASYMP CD8 + T cells, with these functions intact, cause immunologic control of recurrent herpes infection and disease would require passive-transfer studies in humans or experimental animals that develop spontaneous recurrent disease (2) . Unfortunately, mice do not develop spontaneous recurrent disease (reviewed in Ref. 8) . It is likely that other host or viral factors, either alone or in concert with cellular immune responses, also play an important role in determining the course of herpes infection and disease.
Although several factors are likely involved in determining the outcome of herpes infection and disease, accumulating direct evidence in animal models and indirect observations in humans suggest that virus-specific CD8 + T cells mediate control of herpes, although the mechanisms by which this occurs remain unknown (reviewed in Ref. 8) . A recent study by Carr and colleagues (48) evaluated the role of mouse CD8 + T cells in ocular immunity using gBT-I.1 transgenic mice in which >98% of CD8 + T cells are specific for the immunodominant mouse H-2K b -restricted HSV-1 epitope (gB [498] [499] [500] [501] [502] [503] [504] [505] ) and found a significant reduction in virus, elevation in HSV-specific CD8 + T cell influx, and more CD8 + T cells expressing CXCR3 in the cornea of transgenic mice compared with those in the cornea of wild-type controls yet similar acute corneal pathology. However, by day 30 postinfection, wild-type mice had drastically more blood and lymphatic vessel projections into the cornea compared with gBT-I.1 transgenic mice, in which lymphatic vessel growth occurred only in response to vascular endothelial growth factor-C. The study concludes that CD8 + T cells are required to eliminate virus more efficiently from the cornea but play a minimal role in immunopathology as a source of vascular endothelial growth factor-C. The translation of these findings to the human situation, where SYMP and ASYMP CD8 + T cells may be in play, remains to be determined. We recently proposed a novel "symptomatic/ asymptomatic concept," in which inflammatory corneal lesions are not a direct consequence of damage caused by the virus or by autoreactive or bystander T cells, but rather result from the balance between immunopathological T cell responses specific to symptomatic HSV-1 epitopes and immunoprotective T cell responses specific to asymptomatic HSV-1 epitopes (as illustrated in Fig. 7) . Regardless of the mechanism, if SYMP individuals tend to generate CD8 + T cells that recognize SYMP epitopes that differ from ASYMP epitopes, it would be logical to exclude such SYMP epitopes from future herpes vaccines on the grounds that they may exacerbate rather than cure recurrent herpetic disease.
To our knowledge, the current study is the first to report tha 1) CD8 + T cells specific to naturally processed ASYMP HSV-1 CD8 + gB epitopes positively correlate with protection against disease in healthy individuals, whereas 2) CD8 + T cells specific to nonoverlapping SYMP HSV-1 CD8 + epitopes positively correlate with frequently distressing symptomatic outbreaks in SYMP patients. Previous reports indicate that HSV-1 gB, which produces transient protective immunity in humans (6, 12, 49, 50) , is a major target for T cells in seropositive humans (6, 7, 51) . It is likely that the breadth of T cell response may be a critical factor in the outcome of herpes infection and disease. The simultaneous recognition of multiple ASYMP CD8 + T cell epitopes, restricted to HLA-A*02:01 and other HLA class I haplotypes, may confer an advantage on the host, as we previously suggested using murine models of ocular and genital herpes infection (35, 52) . In contrast, simultaneous recognition of multiple SYMP CD8 + T cell epitopes may confer a disadvantage on the host.
Humans are not immunologically naive and often carry multiple pathogens and hence can develop T cells that cross-react between different viruses, members of the same family (53) (54) (55) . However, this is unlikely for the gB epitopes analyzed in this study because 1) alignment of the sequences of the 10 HSV-1 gB T cell epitopes with published sequences of gB proteins from other human herpesviruses (i.e., varicella zoster virus, EBV, and CMV) did not reveal significant sequence homologies that might lead to cross-reactive T cells (Table II) , and 2) the four HLA-A*02:01-restricted immunodominant epitopes reported in this study (gB [342] [343] [344] [345] [346] [347] [348] [349] [350] and gB 561-569 , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , and gB [441] [442] [443] [444] [445] [446] [447] [448] [449] ) as recognized by CD8 + T cells from HLA-A*02:01-positive, HSV-1 seropositive individuals are similarly recognized by CD8 + T cells induced in "pathogen-free" HLA-A*02:01 transgenic mice following HSV-1 ocular infection. A similar pattern of CD8 + T cell responses was detected against the 10 HSV-1 gB epitopes in HLA-A*02:01-positive, HSV-1 seropositive humans and HSV-1-infected, pathogen-free HLA-A*02:01 transgenic mice. These mouse results suggest that CD8 + T cells detected in humans are likely induced by HSV-1 gB epitopes. Thus, although the sequence of gB appears the most highly conserved within the herpesvirus family (56) (57) (58) , no significant sequence similarities were found for the epitopes studied. However, one cannot definitely exclude a cross-reactivity of these HSV-1 gB epitopes with epitopes from other pathogens outside the herpes family.
HLA-A*02 has become an important target for T cell-based immunotherapy reflecting its high prevalence in most populations worldwide, regardless of race and ethnicity (59) (60) (61) (62) . In this study, we performed HLA-A*02 subtyping of SYMP versus ASYM individuals using sequence-specific primer genotyping (29) . The results showed that all but one of the A*02 individuals in our cohort are of HLA-A*02:01 subtype, with the remaining (SYMP) individual being HLA-A*02:06. Although each HLA-A*02 subtype molecule can be expected to have a unique specificity, large overlaps in the repertoires of A*02 molecules have been reported (62) . Indeed, >70% of the peptides that bind HLA-A*02:01, the most common A*02 subtype, with high affinity were found to also bind at least two other of the four next most common A*02-subtypes, including A*02:06 (62). Thus, it is possible that the epitopes characterized in this study may be useful in studies with individuals expressing other A*02 alleles. At the same time, however, although cross-reactivity at the binding level appears to be particularly high in the case of HLA-A*02, also note that differences between the molecules may encompass residues at positions involved in TCR recognition, and thus may be associated with differences that lead to divergence in T cell repertoires.
Although developing an effective herpes vaccine is scientifically feasible, progress has been miserably slow because correlation between the effector arm of the immune system and the infection/disease process continues to puzzle virologists and immunologists (63) . Recently, we have advanced the hypothesis that the ultimate development of an effective herpes vaccine can be drawn from HSV-seropositive ASYMP individuals who manage to "naturally" control recurrent herpetic disease to clinically undetectable levels (64, 65) . The present study showed that ASYMP gB epitopes used as a vaccine protected HLA transgenic mice against ocular herpes infection and disease. In contrast, SYMP gB epitopes provided no protection and might be harmful. We now plan to construct candidate epitope-based vaccines exclusively incorporating ASYMP CD8 + T cell epitopes together with ASYMP human CD4 + T cells epitopes that we recently identified (9) . This should produce the next generation of safe and powerful ASYMP CD4-CD8 vaccines. Additionally, a vaccine covering a wide range of strains of HSV-1 and HSV-2 is highly desirable. In this context, it is important to emphasize that the two HSV-1 CD8 + ASYMP epitopes identified in this study are sequence-identical within, and between, HSV-1 and HSV-2 strains and are appropriate for candidate-type common vaccines. Interestingly, none of the four immunodominant gB epitopes reported in this study was detected in a recent ORFome study by Koelle and colleagues (46) that reported HLA-A*02:01-restricted epitopes from HSV-1. This may be due to differences in the immunological screens, the epitope mapping strategies, and selection of HSV-seropositive individuals used in the two studies.
In conclusion, the current study provides several new insights about the breadth, function, and specificity of a virus-specific CD8 + T cell population that segregates with immunologic control of herpes infection and disease in both ASYMP individuals and in humanized HLA-A*02:01 transgenic mice. We report two previously unknown HLA-A*02:01-restricted ASYMP epitopes derived from HSV-1 gB that tended to recall polyfunctional CD8 + T cell responses in HLA-A*02:01-positive, HSV-seropositive ASYMP humans and protected humanized HLA-A*02:01 transgenic mice from ocular herpes infection and disease. Understanding the detailed mechanisms by which HLA-A*02:01-restricted ASYMP CD8 + T cells are associated with protection against disease will reveal underlying principles of immune control of herpes, which is critical for the rational design of a T cell-based vaccine strategy. The findings demonstrate quantitative and qualitative features of an effective HSVspecific CD8 + T cell response that should be considered in the testing of the next generation of herpes vaccines. Schematic representation showing the relative location within HSV-1 gB of the potential CD8 + T cell epitopes studied. HSV-1 (strain 17) gB regions carrying potential HLA A*0201 (HLA-A*0201)-restricted T cell epitopes were predicted using computer-assisted algorithms based on known HLA/peptide/TCR interactions, as described in Materials and Methods. The amino acid sequence, in a single letter code, and the peptide positions based on the 904-aa sequence of gB are shown. The high-affinity immunodominant epitopes identified in this study are shown in bold. ID, Intracellular domain; SS, signal sequence; TM, transmembrane domain. High frequency of IFN-γ-producing CD8 + T cells specific to gB [17] [18] [19] [20] [21] [22] [23] [24] [25] , gB [183] [184] [185] [186] [187] [188] [189] [190] [191] , gB 342-350 , gB [441] [442] [443] [444] [445] [446] [447] [448] [449] , and gB 561-569 epitopes detected in HLA-A*02:01-positive, HSV-seropositive individuals. PBMC-derived CD8 + T cells were analyzed ex vivo, after in vitro expansion, for the frequency of CD8 + T cells specific to 10 gB peptide/tetramer complexes representing each of the 10 potential gB epitopes shown in Fig. 1 A proposed model of phenotypic and functional characteristics of HSV-specific CD8 + T cells in HSV-seropositive SYMP versus ASYMP individuals. After stimulation with HSV-1 ASYMP epitopes, CD8 + T cells (purple) from HSV-seropositive ASYMP individuals develop more protective CD8 + T cells that prevent herpes disease. In contrast, after stimulation with HSV-1 SYMP epitopes, CD8 + T cells (orange) from SYMP individuals develop more pathogenic CD8 + T cells that lead to inflammation. CD8 + T cells from SYMP individuals secrete substantial amounts of proinflammatory cytokines IL-6, IL-8, and IL-17 (small red circles) and have low proliferation and low lytic granules. In contrast, CD8 + T cells from ASYMP individuals have efficient proliferation and clonal expansion, and they produce more lytic granules and more IL-2, IFN-γ, and TNF-α (small blue circles), resulting in decreased or subclinical disease. In SYMP individuals, lower amounts of lytic granules likely account for inefficient killing of HSV-infected target cells.
Table I
Potential HLA-A*0201-restricted epitopes selected from HSV gB The amino acid residues that are conserved across other human herpesviruses are shown in bold.
